Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and adhesion crossover study of EVRA patch with newly sourced adhesive component
NL-OMON48510Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of ethinyl estradiol + norelgestromin in contraception (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Bioequivalence of norelgestromin and ethinyl estradiol and Patch adhesion. Started Jul 2019; status: completed.
02
Drugs
ethinyl estradiol + norelgestromin
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON48510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48510.